These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 27923859)

  • 21. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
    André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
    J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
    Boltežar L; Pintarić K; Jezeršek Novaković B
    J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
    Stephens DM; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; LaCasce AS; Barr PM; Knopp MV; Hsi ED; Leonard JP; Kahl BS; Smith SM; Friedberg JW
    Blood; 2019 Oct; 134(15):1238-1246. PubMed ID: 31331918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
    Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
    Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
    Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
    Machet A; Poudou C; Tomowiak C; Gastinne T; Gardembas M; Systchenko T; Moya N; Debiais C; Levy A; Gruchet C; Sabirou F; Noel S; Bouyer S; Leleu X; Delwail V; Guidez S
    Blood Adv; 2023 Aug; 7(15):3978-3983. PubMed ID: 36129842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women.
    Pampanini V; Wagner M; Asadi-Azarbaijani B; Oskam IC; Sheikhi M; Sjödin MOD; Lindberg J; Hovatta O; Sahlin L; Björvang RD; Otala M; Damdimopoulou P; Jahnukainen K
    Hum Reprod; 2019 Sep; 34(9):1674-1685. PubMed ID: 31411325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro.
    Rosario R; Stewart HL; Spears N; Telfer EE; Anderson RA
    Hum Reprod; 2024 Feb; 39(2):382-392. PubMed ID: 38070496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
    Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metaphase II oocytes from human unilaminar follicles grown in a multi-step culture system.
    McLaughlin M; Albertini DF; Wallace WHB; Anderson RA; Telfer EE
    Mol Hum Reprod; 2018 Mar; 24(3):135-142. PubMed ID: 29390119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and growth of isolated pre-antral follicles from human ovarian medulla tissue during long-term 3D culture.
    Yin H; Kristensen SG; Jiang H; Rasmussen A; Andersen CY
    Hum Reprod; 2016 Jul; 31(7):1531-9. PubMed ID: 27112699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
    Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
    Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
    Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.